Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX87 with HLX22 or Pertuzumab in HER2+ Breast Cancer
NCT07294534Phase 3Not yet recruiting
- Sponsor
- Henlius
- Start
- Jan 2026
- Primary completion
- Sep 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 3 trial of gq1005 in breast cancer, sponsored by Henlius. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
gq1005
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07294534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07294534.